Copenhagen, Denmark; February 26, 2008 – Genmab A/S (OMX: GEN) announced today that the purchase agreement entered into between Genmab and PDL BioPharma, Inc. under which Genmab would acquire PDL’s antibody manufacturing facility has received antitrust clearance from the US antitrust authorities under the Hart-Scott-Rodino Act.  This transaction was announced February 21, 2008 and is expected to close by the end of the first quarter of 2008.  The US antitrust clearance received today satisfies one of the customary closing conditions required to complete this transaction, which will become effective as soon as all of these conditions have been satisfied